Zelira Therapeutics Stock Price, News & Analysis
Company Description
Zelira Therapeutics (OTC Link: ZLDAF) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $3.0M.
ZLDAF stock has gained 48.6% over the past year. Shares last traded at $0.3283.
This page provides a comprehensive overview of ZLDAF stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Zelira Therapeutics (ZLDAF) stock last traded at $0.3283. Over the past 12 months, the stock has gained 48.6%. At a market capitalization of $3.0M, ZLDAF is classified as a micro-cap stock with approximately 11.9M shares outstanding.
Latest News
Zelira Therapeutics has 3 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 0 with negative movement. View all ZLDAF news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Zelira Therapeutics (ZLDAF) currently stands at 1.1 thousand shares, up 1000.0% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has increased by 124.5%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Zelira Therapeutics (ZLDAF) currently stands at 4.5 days, up 331.7% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 331.7% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 4.5 days.
ZLDAF Company Profile & Sector Positioning
Zelira Therapeutics (ZLDAF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing ZLDAF often look at related companies in the same sector, including Mosaic Immunoengineering Inc (CPMV), Nascent Biotech (NBIO), Eastgate Biotech (ETBI), Aptose Bioscienc (APTOF), and Avenue Therapeutics Inc (ATXI). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ZLDAF's relative position within its industry.